1-(Methylsulfonyl)-4-piperidineethanamine | 946774-36-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(Methylsulfonyl)-4-piperidineethanamine
• 英文别名: 2-(1-methylsulfonylpiperidin-4-yl)ethanamine
• CAS: 946774-36-3
• 化学式: C₈H₁₈N₂O₂S
• 分子量: 206.31
• InChiKey: PRIVWFCRJFHMEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Triterpene amine derivatives
  申请人：DFH THERAPEUTICS

  公开号：US11236122B2

  公开（公告）日：2022-02-01

  The present invention concerns novel pharmaceutically active triterpene amine derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the triterpene amine compounds. Specifically, the compounds are derivatives of betulinic acid having substitutions at one or more of the C-3, C-28 and C-19 positions as further described herein. The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus-1 (HIV-1).

  本发明涉及新型具有药用活性的三萜胺衍生物、含有三萜胺衍生物的药物组合物、其作为药物的用途，以及使用这些化合物制造特定药物。本发明还涉及一种涉及三萜胺化合物给药的治疗方法。具体来说，这些化合物是白桦脂酸的衍生物，在 C-3、C-28 和 C-19 位上有一个或多个取代位，如本文进一步描述的那样。这些新型化合物可用作抗逆转录病毒药物。特别是，这些新型化合物可用于治疗人类免疫缺陷病毒-1（HIV-1）。
• MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
  申请人：AbbVie Inc.

  公开号：EP3668503A1

  公开（公告）日：2020-06-24
• TRITERPENE AMINE DERIVATIVES
  申请人：DFH THERAPEUTICS

  公开号：US20210253627A1

  公开（公告）日：2021-08-19

  The present invention concerns novel pharmaceutically active triterpene amine derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the triterpene amine compounds. Specifically, the compounds are derivatives of betulinic acid having substitutions at one or more of the C-3, C-28 and C-19 positions as further described herein. The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus-1 (HIV-1).
• US8288431B2
  申请人：——

  公开号：US8288431B2

  公开（公告）日：2012-10-16
• US9815851B2
  申请人：——

  公开号：US9815851B2

  公开（公告）日：2017-11-14